ClinicalTrials.gg
CompletedNCT07686705Updated Oct 5, 2026

Intravenous Versus Intra-articular Tranexamic Acid for Visual Clarity During Arthroscopic Rotator Cuff Repair

An interventional study of Tranexamic acid (intra-articular) and Tranexamic acid (intravenous) in Rotator Cuff Tears, sponsored by Konkuk University Medical Center. Completed at 1 site in South Korea. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Konkuk University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled May 2023, registered Jun 2026).
Updated Oct 5, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of — 3 open to participants now, 4 under way, 1 of them phase 3. Rotator Cuff Injuries · Korea, Republic of.

Enrollment
5th of 25
115 · median 74
Started
2023
with 1 other
No phase
17 of 30
1 open now
Registered
28th of 30
by date

Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 17 with no phase, and was the 28th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

3 of the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This single-center, prospective, randomized, double-blind controlled trial evaluated whether intravenous (IV) or intra-articular (IA) administration of tranexamic acid (TXA) improves intraoperative visual clarity, compared with a no-TXA control, during arthroscopic rotator cuff repair. Patients with rotator cuff tears were randomly allocated to one of three groups: a control group receiving no TXA; an IA group in which 500 mg of TXA was added to each 1 L of normal-saline irrigation fluid; and an IV group receiving 1000 mg of TXA intravenously 10 minutes before surgery. The operating surgeon graded visual clarity on a 0-10 numeric scale at the end of each of six predefined surgical stages. Secondary outcomes included total operative time, estimated blood loss, irrigation-fluid volume, the number of irrigation-pressure increases, postoperative shoulder swelling, and postoperative day 1 pain.

03

Conditions studied

  • Rotator Cuff Tears

Browse trials for

Keywords

  • rotator cuff repair
  • tranexamic acid
  • visual clarity
  • shoulder arthroscopy
  • intra-articular administration
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Diagnosed with a rotator cuff tear
  • Failure of conservative treatment for more than 3 months
  • Rotator cuff deemed repairable on magnetic resonance imaging

Exclusion criteria

Exclusion Criteria:

  • Known to tranexamic acid
  • Previous cerebrovascular accident
  • Coronary stent or other history of thromboembolic disease
  • Anticoagulant therapy
  • Uncontrolled hypertension (systolic pressure > 180 mmHg)
  • Abnormal or activated partial thromboplastin time
  • Acute traumatic rotator cuff tear
  • Irreparable rotator cuff tear
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • No intervention
    Control

    No tranexamic acid; arthroscopic rotator cuff repair performed with plain normal-saline irrigation.

  • Experimental
    Intra-articular TXA

    Tranexamic acid 500 mg added to each 1 L of normal-saline irrigation fluid during arthroscopic rotator cuff repair.

    Drug: Tranexamic acid (intra-articular)

  • Experimental
    Intravenous TXA

    Tranexamic acid 1000 mg administered intravenously 10 minutes before surgery; plain normal-saline irrigation as in the control group.

    Drug: Tranexamic acid (intravenous)

Interventions

06

What researchers measure

Primary outcomes

  1. Intraoperative visual clarity

    Surgeon-rated clarity of the arthroscopic surgical field on a 0-10 numeric scale (0 = poorest visualization, 10 = optimal visualization), scored at the end of each of six surgical stages: glenohumeral procedure, subacromial bursectomy, acromioplasty, rotator cuff inspection, medial-row repair, and lateral-row repair.

    Time frame: Intraoperatively, at the end of each of the six surgical stages

Secondary outcomes

  1. Total operative time

    Total duration of the surgical procedure.

    Time frame: Intraoperative (duration of surgery)

  2. Estimated blood loss

    Estimated blood loss calculated from serum hemoglobin measured before and after surgery using the formula described by Good et al.

    Time frame: postoperative day 1

  3. Irrigation-fluid volume

    Total volume of irrigation fluid used during the procedure.

    Time frame: Intraoperatively, from skin incision to skin closure (duration of surgery)

  4. Number of irrigation-pressure increases

    Number of times the irrigation pump pressure was increased to control bleeding affecting the surgical field

    Time frame: Intraoperatively, from skin incision to skin closure (duration of surgery)

  5. Postoperative shoulder swelling

    Shoulder circumference and diameter measured at the axillary and deltoid sites with the arm abducted \~30 degrees, compared between pre-operative and postoperative day 1

    Time frame: Baseline (pre-operative) and postoperative day 1

  6. Postoperative pain

    Pain assessed using a visual analog scale (VAS) on postoperative day 1

    Time frame: Pain assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate worse outcome, on postoperative day 1

07

Study locations

1 site
  • Konkuk University Medical Center
    Seoul, Seoul 05030, South Korea
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2024, 15 months.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start May 2022 → May 2023, primary completion Aug 2023 → Aug 2024 and completion Aug 2023 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 7, 2026
StartActual
May 18, 2023was May 2022
Primary completionActual
Aug 25, 2024was Aug 2023
CompletionActual
Aug 26, 2024was Aug 2023
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 18, 2022→May 18, 2023
Oct 5, 2026
Primary completion
Aug 25, 2023→Aug 25, 2024
Oct 5, 2026
Study completion
Aug 26, 2023→Aug 26, 2024
Oct 5, 2026
Enrollment
122→115
Oct 5, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameEstimated blood lossFrom immediately before surgery to immediately after the end of surgery → postoperative day 1
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date May 18, 2022→May 18, 2023
    Primary completion Aug 25, 2023→Aug 25, 2024
    Study completion Aug 26, 2023→Aug 26, 2024
    Enrollment 122→115
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameEstimated blood lossFrom immediately before surgery to immediately after the end of surgery → postoperative day 1
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07686705
Lead sponsor
Konkuk University Medical Center
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
May 18, 2023
Primary completion
Aug 25, 2024
Completion
Aug 26, 2024
Last update
Oct 5, 2026

Study contacts

Seok Won Chung, MD
principal investigator · Konkuk University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion